DUBLIN, Oct. 25, 2016 /PRNewswire/ -- Studies show
that more than two-thirds of aesthetically-oriented consumers are
bothered by submental fullness, or "double chin."1 And
with social media profile images becoming more important than ever,
there is interest in looking one's best.
Experience the interactive Multimedia News Release here:
https://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign
Submental fullness due to fat beneath the chin can impact a
broad range of both men and women and because the condition can be
genetic and resistant to diet and exercise.2 But there's
KYBELLA®, the first and only FDA-approved injectable
treatment that is available by prescription only, that has
been proven to improve the appearance of moderate to severe fat
beneath the chin by physically destroying fat cells in the
treatment area.3 In two pivotal clinical studies
for KYBELLA®, reductions in submental fat volume were
observed more frequently in the KYBELLA® treated group
of 514 patients compared to the placebo group (508 patients) as
measured by both clinician and patient ratings. In addition, visual
and emotional impacts of submental fat (happy, bothered,
self-conscious, embarrassed, looking older or overweight) were
evaluated using a 6-question survey and 79% of 1
and 2-grade composite responders reported satisfaction after 12
weeks post final treatment compared with 33.6% of patients who
received placebo.3
KYBELLA® can cause serious side effects including
nerve injury in the jaw that can cause an uneven smile or facial
muscle weakness and trouble swallowing. The most common side
effects are swelling, bruising, pain, numbness, redness, and areas
of hardness in the treatment area.3
"The extraordinary reach of social media means our image is
everywhere these days," says photographer Peter Hurley, author of The Headshot,
"but unfortunately I have a lot clients tell me they actually avoid
appearing in social media photos because they're unhappy or feel
self-conscious about the way they look in these images."
So to help men and women everywhere put their best profiles
forward on social media, KYBELLA®, gathered a panel of
profile experts to develop tips and tricks to help people improve
their social media profile photos.
Photographer Peter Hurley
recommends the following photo strategies:
- On your feet: Sitting for a photo can add weight
(especially if you slouch). I prefer my clients to stand, which
just naturally elongates the body."
- Find the right chin angle: "In my studio, the
positioning of a subject's chin is one of the first things I
discuss before we shoot. The best way to ensure a strong chin angle
is to face the camera and bring your forehead toward the camera and
slightly down. Once your chin is in the right position, imagine
there's a hook attached to the crown of your head that's pulling
you toward the ceiling. Your goal is to elongate the neck and
tighten the skin around your jawline so the light can wrap around
it more sharply."
- Don't forget to squinch: "Squinching" is a technique I
made up for my clients to help them look more attractive and
approachable. To "squinch," bring your lower eyelids up slightly
toward your pupils. Practice in a mirror and you'll notice a subtle
but impactful difference."
- Hold a sub: "To slim your upper arms and shoulders,
position yourself as if you are holding a large sub sandwich with
your elbows tucked into your sides. Then widen your hands as if
holding a 6 foot-long sub, with your elbows still tucked. The
difference is incredible."
- The best background: "My headshots are typically done on
a white background, which is clean and simple. I also prefer a
close horizontal crop. The open space it creates around a subject
can be very impactful and creates what I call "lookability," which
is the ability of an image to get attention."
- The right crop: "After you have an image you like, it's
time to crop it effectively. I like to zoom in and crop a little
off the top of a subject's head. This puts the eyes above the
centerline of the image and calls attention to the chin line and
shoulders as well."
But it's not just about looking great in that selfie. Having the
wrong social media profile picture can also be bad business.
"Social media has given everyone the opportunity to be their own
brand and allow potential employers to see who you are beyond your
résumé, cover letter, or interview," says Maggie Mistal, career counselor and host of the
podcast "Make a Living with Maggie. "And of course your photo is an
important component of your social profile."
To create or select a profile photo that may help get a
hiring manager's attention, Career Counselor Maggie Mistal has the
following tips:
- Go it alone: "Make sure your image is a
professional-looking headshot of you alone. Avoid cropping other
people out of photos, which never looks professional, and avoid
distracting backgrounds like tourist landmarks."
- Say cheese: "Look at the camera and smile. Your image
and facial expression should draw people in for a closer
look. You want people to be interested in who you are and
excited about getting to know you better."
- Be consistent: "Once you have a winning image use it
across all your channels – not just LinkedIn. Don't assume because
you use Facebook to connect with friends and family a prospective
employer won't look there."
- Beyond the profile photo: "Remove any photos that depict
you in an unflattering way (and I don't mean physically), but be
sure to share photos that give employers a positive look at your
life and interests outside of work. For example, if you run
marathons or volunteer in the community, make sure to share those
photos.
To start the conversation and motivate people to learn more
about KYBELLA®, the brand launched a new
direct-to-consumer campaign, designed to resonate with men and
women who have a double chin and introduce them to this minimally
invasive injectable treatment for moderate to severe fat under the
chin. The national TV campaign emphasizes that double chin isn't
just caused by aging – it can also be genetic. And with
KYBELLA® you can do something about that double chin you
"inherited."
To learn more about submental fullness and the Live Chin Up
Campaign, visit www.LiveChinUp.com. To learn more about
KYBELLA® and find a physician in your area visit
www.MyKybella.com
KYBELLA® Approved Use and Important Safety
Information
What is KYBELLA®?
KYBELLA® is a
prescription medicine used in adults to improve the appearance and
profile of moderate to severe fat below the chin (submental fat),
also called "double chin."
It is not known if KYBELLA® is safe and effective for
use outside of the submental area or in children under the age of
18.
Who should not receive KYBELLA®?
You should
not receive KYBELLA® if you have an infection in the
treatment area.
Before receiving KYBELLA®, tell your healthcare
provider about all of your medical conditions, including if
you: Have had or plan to have surgery on your face, neck, or
chin; have had cosmetic treatments on your face, neck, or chin;
have had or have medical conditions in or near the neck area; have
had or have trouble swallowing; have bleeding problems; are
pregnant or plan to become pregnant (it is not known if
KYBELLA® will harm your unborn baby); are breastfeeding
or plan to breastfeed (it is not known if KYBELLA®
passes into your breast milk; talk to your healthcare provider
about the best way to feed your baby if you receive
KYBELLA®).
Tell your healthcare provider about all the medicines you
take, including prescription and over-the counter medicines,
vitamins, and herbal supplements. Especially tell your healthcare
provider if you take a medicine that prevents the clotting of your
blood (antiplatelet or anticoagulant medicine).
What are the possible side effects of
KYBELLA®?
KYBELLA® can cause serious side effects,
including nerve injury in the jaw (which can cause an uneven
smile or facial muscle weakness), or trouble swallowing.
The most common side effects of KYBELLA®
include: swelling, bruising, pain, numbness, redness, and areas
of hardness in the treatment area.
These are not all of the possible side effects of
KYBELLA®. Call your healthcare provider for medical
advice about side effects.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/safety/MedWatch or
call 1-800-FDA-1088.
Please talk to your healthcare provider or visit
www.mykybella.com for full Prescribing Information.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceuticals, devices
and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's
R&D model, which defines our approach to identifying and
developing game-changing ideas and innovation for better patient
care. This approach has led to Allergan building one of the
broadest development pipelines in the pharmaceutical industry with
70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we
build bridges, power ideas, act fast and drive results for our
customers and patients around the world by always doing what is
right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website at
www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2015 and Quarterly Report on Form 10-Q for the quarter ended
June 30, 2016 (such periodic public
filings having been filed under the "Actavis plc" name). Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
References
1. American Society for
Dermatologic Surgery 2015 Consumer Survey on Cosmetic Dermatologic
Procedures, 2015. "How Bothered Are You By Excess Fat Under The
Chin/Neck?"
2. Schlessinger J, Weiss SR, Jewell M, Narurkar V,
Weinkle S, Gold MH, Bazerkanian E. Perceptions and Practices in
Submental Fat Treatment: A Survey of Physicians and Patients.
SKINmed Dermatology for the Clinician. 2013; 11(1):27-31.
3. KYBELLA® Prescribing Information,
2015.
© 2016 Allergan. All rights reserved. All trademarks are the
property of their respective owners.
KYB102113 09/16
CONTACTS:
Investors:
Lisa
DeFrancesco
(862) 261-7152
Media:
Mark Marmur
(862) 261-7558
Ember Garrett
(714) 246-3525
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kybella-deoxycholic-acid-injection-10-mgml-puts-profiles-in-focus-with-expert-panel-and-new-direct-to-consumer-campaign-300350408.html
SOURCE Allergan plc